@article{oai:shiga-med.repo.nii.ac.jp:00003825,
 author = {熊谷, 康佑 and 奥村, 法昭 and 天野, 泰孝 and 彌山, 峰史 and 三村, 朋大 and 前田, 勉 and 久保, 充彦 and 森, 幹士 and 今井, 晋二 and KUMAGAI, Kosuke and OKUMURA, Noriaki and AMANO, Yasutaka and YAYAMA, Takafumi and MIMURA, Tomohiro and MAEDA, Tsutomu and KUBO, Mitsuhiko and MORI, Kanji and Barrett-Jolley, Richard and IMAI, Shinji},
 journal = {Modern rheumatology},
 month = {Feb},
 note = {pdf, Objectives:
Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital., Methods:
Demographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190)., Results:
There was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA., Conclusion:
Patients with EORA may be able to achieve LDA with lower drug dosage than those with YORA., Journal Article},
 pages = {1--10},
 title = {Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity.},
 year = {2021}
}